Gefitinib in Treating Patients With Malignant Mesothelioma

NCT00025207 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Mesothelioma
Epithelial Mesothelioma
Recurrent Malignant Mesothelioma
Sarcomatous Mesothelioma

Interventions

DRUG: gefitinib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)